Novartis in advanced discussions to acquire Cytokinetics
The deal is expected to grant Novartis access to Cytokinetics' experimental treatment for hypertrophic cardiomyopathy treatment, Aficamten, which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Jan 24
The deal is expected to grant Novartis access to Cytokinetics' experimental treatment for hypertrophic cardiomyopathy treatment, Aficamten, which…
09 Jan 24
EU health regulator has approved the combination for adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom…
09 Jan 24
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand
09 Jan 24
bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of LUMED, a software company that…
09 Jan 24
The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate…
08 Jan 24
In addition to the acquisition of SanReno, Novartis has secured the US FDA approval for commercial manufacturing of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Jan 24
The products covered by the agreement are Ascendis Pharma's Skytrofa (lonapegsomatropin), a weekly injectable paediatric human growth hormone…
08 Jan 24
In the trial, the vaccine demonstrated non-inferiority to Shingrix as measured by humoral immune response along with reduced…
08 Jan 24
The effectiveness of Zelsuvmi was proven in the B-SIMPLE 4 and B-SIMPLE 2 Phase 3 trials in which…
08 Jan 24
Both companies will work together to study potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune…